文章：

Pyk2激酶在胶质母细胞瘤进展及治疗靶向中的作用

The Role of Pyk2 Kinase in Glioblastoma Progression and Therapeutic Targeting

原文发布日期：9 August 2025

DOI: 10.3390/cancers17162611

类型: Article

开放获取: 是

英文摘要：

Glioblastoma (GBM) is a highly aggressive brain tumor with limited treatment options and poor prognosis. Proline-rich tyrosine kinase 2 (Pyk2) has been implicated in regulation of GBM invasion, proliferation, and recurrence. Its activation, driven by tumor-infiltrating microglia and macrophage-derived extracellular factors such as EGF, PDGFB, SDF-1α, IL-6, and IL-8, enhances tumor cell motility and survival. Experimental studies demonstrate that pharmacological inhibition or genetic knockdown of Pyk2 significantly reduces glioma cell migration and proliferation. Furthermore, recurrent GBM tumors exhibit elevated Pyk2 phosphorylation in mouse GBM models, correlating with increased tumor growth. Inhibition of Pyk2 and the structurally related focal adhesion kinase (FAK) signaling has shown promising results in preclinical studies, reducing tumor recurrence and improving survival outcomes. This review summarizes recent findings and underscores the pivotal role of Pyk2 in GBM pathophysiology, highlighting its potential as a therapeutic target.

摘要翻译： 

胶质母细胞瘤（GBM）是一种高度侵袭性脑肿瘤，治疗手段有限且预后不良。富含脯氨酸的酪氨酸激酶2（Pyk2）已被证实参与调控GBM的侵袭、增殖及复发过程。该激酶在肿瘤浸润小胶质细胞和巨噬细胞来源的细胞外因子（如EGF、PDGFB、SDF-1α、IL-6和IL-8）驱动下激活，进而增强肿瘤细胞的运动能力与存活率。实验研究表明，通过药物抑制或基因敲低Pyk2能显著降低胶质瘤细胞的迁移与增殖能力。此外，在小鼠GBM模型中，复发性GBM肿瘤表现出Pyk2磷酸化水平升高，这与肿瘤生长加速密切相关。临床前研究显示，抑制Pyk2及其结构相关的黏着斑激酶（FAK）信号通路能有效降低肿瘤复发率并改善生存预后，展现出良好的治疗前景。本文综述了最新研究进展，系统阐述了Pyk2在GBM病理生理中的关键作用，并强调其作为治疗靶点的潜在价值。

原文链接：

The Role of Pyk2 Kinase in Glioblastoma Progression and Therapeutic Targeting